Moderate to Severe Ulcerative Colitis
Immunology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Connect BiopharmaDouble-Blind 0.2mg CBP-307
GenentechVixarelimab
Clinical Trials (2)
Total enrollment: 24 patients across 2 trials
A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
Start: Feb 2019Est. completion: Nov 2022
Phase 2Completed
A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis
Start: Mar 2025Est. completion: Jun 202624 patients
Phase 1/2Recruiting
Related Jobs in Immunology
Regulatory Affairs Manager(Immunology), Korea
AbbVie
Seoul, Seoul
15h ago
Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)
AbbVie
Remote
15h ago
Field Reimbursement Manager - Rheumatology - Seattle, WA (North)
Johnson & Johnson
Seattle, Washington, United States of America
Yesterday
$100K - $175K/yr
Senior Medical Science Liaison, Dermatology - Indianapolis
Johnson & Johnson
Indianapolis, Indiana, United States
Yesterday
$137K - $236K/yr
Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine
Johnson & Johnson
Detroit, Michigan, United States
Yesterday
Supply Chain and Procurement Controller
Ferring Pharmaceuticals
Hvidovre, Denmark
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 24 patients
Monoclonal Antibody is the dominant modality (100% of programs)
2 companies competing in this space